Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Cancer Res. 2010 Nov 1;70(21):8886-95. doi: 10.1158/0008-5472.CAN-10-0171. Epub 2010 Oct 12.

    Ionizing radiation activates the Nrf2 antioxidant response.

    Source

    Division of Molecular and Cellular Oncology, Department of Radiation Oncology, and Pasarow Mass Spectrometry Laboratory, David Geffen School of Medicine at University of California, Los Angeles, California 90095-1714, USA.

    Abstract

    The transcription factor NF-E2-related factor 2 (Nrf2) binds the antioxidant DNA response element (ARE) to activate important cellular cytoprotective defense systems. Recently several types of cancers have been shown to overexpress Nrf2, but its role in the cellular response to radiation therapy has yet to be fully determined. In this study, we report that single doses of ionizing radiation from 2 to 8 Gy activate ARE-dependent transcription in breast cancer cells in a dose-dependent manner, but only after a delay of five days. Clinically relevant daily dose fractions of radiation also increased ARE-dependent transcription, but again only after five days. Downstream activation of Nrf2-ARE-dependent gene and protein markers, such as heme oxygenase-1, occurred, whereas Nrf2-deficient fibroblasts were incapable of these responses. Compared with wild-type fibroblasts, Nrf2-deficient fibroblasts had relatively high basal levels of reactive oxygen species that increased greatly five days after radiation exposure. Further, in vitro clonogenic survival assays and in vivo sublethal whole body irradiation tests showed that Nrf2 deletion increased radiation sensitivity, whereas Nrf2-inducing drugs did not increase radioresistance. Our results indicate that the Nrf2-ARE pathway is important to maintain resistance to irradiation, but that it operates as a second-tier antioxidant adaptive response system activated by radiation only under specific circumstances, including those that may be highly relevant to tumor response during standard clinical dose-fractionated radiation therapy.

    ©2010 AACR.

    PMID:
    20940400
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2970706
    Free PMC Article

    Images from this publication.See all images (6)Free text

    Figure 1
    Figure 2
    Figure 3
    Figure 4
    Figure 5
    Figure 6

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk